"Mount Sinai and Novotalk Sign Joint Venture Agreement to Bring Innovative Speech and Language Technologies To Patients"
Mount Sinai Health System (MSHS) and Novotalk, Ltd., entered into an exclusive joint venture agreement to commercialize innovative speech and language solutions to address the therapeutic need of patients with speech impairments in the United States and Canada. The first product to be launched uses on-demand tele-therapy to provide a lifelong solution to people with chronic stuttering, which affects approximately 1 percent of the global population. "Mount Sinai aims to advance breakthroughs that benefit patients. We look forward to expanding Novotalk's proven capabilities in delivering on-demand tele-therapy to our clinical setting, so that we may better serve our patient population," said Erik Lium, PhD, executive vice president of Mount Sinai Innovation Partners. As part of the partnership between MSHS and Novotalk, Dr. Lium will join the board of Novotalk, Inc., while Bruce Darrow, MD, PhD, Chief Medical Information Officer for MSHS, will be added to the advisory board of the company. In addition, Mount Sinai Ventures has decided to make a financial investment in Novotalk, following due diligence and competitive market analysis.
- Erik Lium, PhD, Executive Vice President, Mount Sinai Innovation Partners
- Bruce Darrow, MD, PhD, Associate Professor, Medicine, Cardiology, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, Vice President, Information Technology, Mount Sinai Health System
Crain’s Health Pulse (Subscription required)